Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

Appointment of Non-Executive Director and Senior Independent Director

Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce the appointment of Martin Sutherland as a new independent Non-Executive Director and Richard Jones, a Non-Executive Director since 2019, as Senior Independent Director to strengthen the Board and support the delivery of the Company's growth strategy.

Martin, who will join the Board with immediate effect, is a senior executive with over 30 years' experience in global businesses. He is currently a NED at FTSE listed Forterra plc and Reliance acsn ltd. Forterra is a leading UK manufacturer of essential clay and concrete building products. Martin joined the Board of Forterra in 2017 and sits on the Nomination, Remuneration, Audit, and Risk & Sustainability committees. Reliance acsn ltd is a privately held specialist cyber security business, a company which he joined in 2020 as CEO and helped to drive a doubling of revenues in two years. Martin stepped down as CEO to become NED in January 2023.

Martin was CEO of De La Rue plc between 2014 and 2019 and previously held various roles at Detica plc, becoming Managing Director in 2008 on its acquisition by BAE Systems plc. Martin has a proven track record of delivering growth through new product innovation, market diversification and international expansion. We believe that Martin's experience will bring a new perspective to complement the strong consumer healthcare knowledge already present on the Board.

Following its annual review, the Board has decided to appoint Richard Jones, current NED and Chair of Audit & Risk Committee, as Senior Independent Director with immediate effect. Richard is CFO of Medica Group plc, the UK's leading teleradiology provider, and has been on the Alliance Board since 1 January 2019.

David Cook, Chair of Alliance, said:

"I am delighted to welcome Martin Sutherland to the Board and look forward to his contribution to support the delivery of our growth strategy. Martin will bring significant additional expertise from his experience as a company director and in senior executive leadership roles. The Board will also benefit from his 30 years' experience in managing global businesses and delivering growth.

"I am also pleased to appoint Richard Jones as our first Senior Independent Director. Richard will help support and expand our stakeholder engagement programme, building on his extensive experience in capital markets and leveraging his strong networks with shareholders."

The following information is disclosed pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies.

Mr Martin Conrad Sutherland, aged 54, has been a director of the following companies during the five years preceding the date of this announcement:

Mr Sutherland does not hold any ordinary shares of 1 pence each in the Company.

For further information:

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com